Literature DB >> 12708637

Pharmacologic characteristics of statins.

James M McKenney1.   

Abstract

Considerable effort has been devoted to improving the pharmacologic characteristics and clinical effects of statins. Desirable pharmacologic properties include potent inhibition of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, selectivity of uptake in hepatocytes, low systemic bioavailability to reduce systemic adverse effects, prolonged elimination half-life, and no or minimal hepatic metabolism to avoid drug-drug interactions. The desirable effects on lipid variables would include increased effectiveness in reducing levels of low-density lipoprotein cholesterol and other atherogenic lipoproteins and measurable beneficial effects on high-density lipoprotein cholesterol levels. As a product of the ongoing efforts regarding statin pharmacology, the new statin rosuvastatin exhibits significant improvements in several of these characteristics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12708637      PMCID: PMC6654766          DOI: 10.1002/clc.4960261507

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  19 in total

Review 1.  Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians.

Authors:  M Bottorff; P Hansten
Journal:  Arch Intern Med       Date:  2000 Aug 14-28

2.  Structural mechanism for statin inhibition of HMG-CoA reductase.

Authors:  E S Istvan; J Deisenhofer
Journal:  Science       Date:  2001-05-11       Impact factor: 47.728

3.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

Review 4.  HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles.

Authors:  S L Beaird
Journal:  J Am Pharm Assoc (Wash)       Date:  2000 Sep-Oct

5.  Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia.

Authors:  M Miller; C Dolinar; W Cromwell; J D Otvos
Journal:  Am J Cardiol       Date:  2001-01-15       Impact factor: 2.778

6.  Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.

Authors:  J M McKenney; L S McCormick; E J Schaefer; D M Black; M L Watkins
Journal:  Am J Cardiol       Date:  2001-08-01       Impact factor: 2.778

7.  Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels.

Authors:  C M Ballantyne; T C Andrews; J A Hsia; J H Kramer; C Shear
Journal:  Am J Cardiol       Date:  2001-08-01       Impact factor: 2.778

8.  Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate.

Authors:  C Kyrklund; J T Backman; K T Kivistö; M Neuvonen; J Laitila; P J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  2001-05       Impact factor: 6.875

9.  Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.

Authors:  F McTaggart; L Buckett; R Davidson; G Holdgate; A McCormick; D Schneck; G Smith; M Warwick
Journal:  Am J Cardiol       Date:  2001-03-08       Impact factor: 2.778

10.  Plasma concentrations of active simvastatin acid are increased by gemfibrozil.

Authors:  J T Backman; C Kyrklund; K T Kivistö; J S Wang; P J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  2000-08       Impact factor: 6.875

View more
  43 in total

1.  Simvastatin enhances aquaporin-2 surface expression and urinary concentration in vasopressin-deficient Brattleboro rats through modulation of Rho GTPase.

Authors:  Wei Li; Yan Zhang; Richard Bouley; Ying Chen; Toshiyuki Matsuzaki; Paula Nunes; Udo Hasler; Dennis Brown; Hua A Jenny Lu
Journal:  Am J Physiol Renal Physiol       Date:  2011-04-20

2.  Statins and Breast Cancer: Future Directions in Chemoprevention.

Authors:  Cesar A Santa-Maria; Vered Stearns
Journal:  Curr Breast Cancer Rep       Date:  2013-09-01

Review 3.  Differential metabolic actions of specific statins: clinical and therapeutic considerations.

Authors:  Soo Lim; Ichiro Sakuma; Michael J Quon; Kwang Kon Koh
Journal:  Antioxid Redox Signal       Date:  2013-09-24       Impact factor: 8.401

4.  Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice.

Authors:  Marleen Schonewille; Jan Freark de Boer; Laura Mele; Henk Wolters; Vincent W Bloks; Justina C Wolters; Jan A Kuivenhoven; Uwe J F Tietge; Gemma Brufau; Albert K Groen
Journal:  J Lipid Res       Date:  2016-06-16       Impact factor: 5.922

Review 5.  The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications.

Authors:  Iain P Hargreaves; Andrew J Duncan; Simon J R Heales; John M Land
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 6.  Innovations in asthma therapy: is there a role for inhaled statins?

Authors:  Amir A Zeki; Mona Elbadawi-Sidhu
Journal:  Expert Rev Respir Med       Date:  2018-05-03       Impact factor: 3.772

Review 7.  The current evidence on statin use and prostate cancer prevention: are we there yet?

Authors:  Mahmoud A Alfaqih; Emma H Allott; Robert J Hamilton; Michael R Freeman; Stephen J Freedland
Journal:  Nat Rev Urol       Date:  2016-10-25       Impact factor: 14.432

8.  Fluvastatin modulates renal water reabsorption in vivo through increased AQP2 availability at the apical plasma membrane of collecting duct cells.

Authors:  Giuseppe Procino; Claudia Barbieri; Monica Carmosino; Grazia Tamma; Serena Milano; Leonarda De Benedictis; Maria Grazia Mola; Yoskaly Lazo-Fernandez; Giovanna Valenti; Maria Svelto
Journal:  Pflugers Arch       Date:  2011-08-20       Impact factor: 3.657

9.  Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer.

Authors:  Denise M Boudreau; Onchee Yu; Jessica Chubak; Heidi S Wirtz; Erin J Aiello Bowles; Monica Fujii; Diana S M Buist
Journal:  Breast Cancer Res Treat       Date:  2014-02-21       Impact factor: 4.872

10.  Rosuvastatin Modulates the Post-Translational Acetylome in Endothelial Cells.

Authors:  Ming Chung Lin; Chung Hsi Hsing; Fu An Li; Chien Hsing Wu; Yaw Syan Fu; Jen Kun Cheng; Bin Huang
Journal:  Acta Cardiol Sin       Date:  2014-01       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.